Literature DB >> 26922745

Diagnostic Advances in Multiple Myeloma.

Kevin Barley1, Ajai Chari2.   

Abstract

There have been several advances in the diagnosis of multiple myeloma (MM) in recent years. Serum free light chains have improved the ability to diagnose light chain MM; however, there are still difficulties in the serologic diagnosis of MM in some cases, particularly IgA MM. A novel heavy/light chain assay is able to improve the accuracy of diagnosis in these cases. Free light chains may also improve the diagnosis of extramedullary disease in difficult cases such as disease involving the central nervous system, pleura, or ascites. Advances in imaging such as whole body low-dose computed tomography (CT) whole body magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) have improved sensitivity in identifying lytic bone lesions, which would enable earlier treatment, and monitoring of osseous disease particularly in non- or oligosecretory disease. New techniques such as fused PET/MRI may further enhance the diagnosis of both bone lesions and extramedullary disease.

Entities:  

Keywords:  Diagnosis; Extramedullary disease; Free light chains; HevyLite; Multiple myeloma; Whole body low-dose CT

Mesh:

Substances:

Year:  2016        PMID: 26922745     DOI: 10.1007/s11899-016-0314-5

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  41 in total

1.  The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion.

Authors:  Ayato Tsukamoto; Yumiko Yoshiki; Sho Yamazaki; Keiki Kumano; Fumihiko Nakamura; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2014-03       Impact factor: 3.673

2.  Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

Authors:  L A Moulopoulos; D Gika; A Anagnostopoulos; K Delasalle; D Weber; R Alexanian; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

3.  Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.

Authors:  Marius Horger; Claus D Claussen; Ulrike Bross-Bach; Reinhard Vonthein; Tobias Trabold; Martin Heuschmid; Christina Pfannenberg
Journal:  Eur J Radiol       Date:  2005-05       Impact factor: 3.528

4.  MRI negative meningeal myeloma with abducens nerve palsies responding to intrathecal chemotherapy.

Authors:  A Grisold; C Weber; J Hainfellner; H Gisslinger; G Kasprian; E Auff; T Sycha; W Grisold
Journal:  J Neurol Sci       Date:  2014-10-29       Impact factor: 3.181

5.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

Authors:  Cristina Nanni; Elena Zamagni; Mohsen Farsad; Paolo Castellucci; Patrizia Tosi; Delia Cangini; Eugenio Salizzoni; Romeo Canini; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-02       Impact factor: 9.236

6.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

7.  Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Authors:  Tobias Bäuerle; Jens Hillengass; Kerstin Fechtner; Christian M Zechmann; Lars Grenacher; Thomas M Moehler; Heiss Christiane; Barbara Wagner-Gund; Kai Neben; Hans-Ulrich Kauczor; Hartmut Goldschmidt; Stefan Delorme
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

8.  Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma.

Authors:  Thierry Le Bricon; Djaouida Bengoufa; Mourad Benlakehal; Bernard Bousquet; Danielle Erlich
Journal:  Clin Biochem       Date:  2002-10       Impact factor: 3.281

Review 9.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).

Authors:  T G Gleeson; J Moriarty; C P Shortt; J P Gleeson; P Fitzpatrick; B Byrne; J McHugh; M O'Connell; P O'Gorman; S J Eustace
Journal:  Skeletal Radiol       Date:  2008-11-14       Impact factor: 2.199

View more
  5 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Hematuria as the first sign of multiple myeloma.

Authors:  Mariana Alves; Raul Moreno; Fátima Rodrigues; Anabela Rodrigues; Teresa Fonseca
Journal:  Clin Case Rep       Date:  2017-07-10

3.  PET/MRI: a novel hybrid imaging technique. Major clinical indications and preliminary experience in Brazil.

Authors:  Taise Vitor; Karine Minaif Martins; Tudor Mihai Ionescu; Marcelo Livorsi da Cunha; Ronaldo Hueb Baroni; Marcio Ricardo Taveira Garcia; Jairo Wagner; Guilherme de Carvalho Campos; Solange Amorim Nogueira; Elaine Gonçalves Guerra; Edson Amaro
Journal:  Einstein (Sao Paulo)       Date:  2017 Jan-Mar

4.  [The value of serum heavy/light chain immunoassay to assess therapeutic response in patients with multiple myeloma].

Authors:  X C Yu; W Su; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14

5.  Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.

Authors:  Alexander Zheleznyak; Matthew Mixdorf; Lynne Marsala; Julie Prior; Xiaoxia Yang; Grace Cui; Baogang Xu; Steven Fletcher; Francesca Fontana; Gregory Lanza; Samuel Achilefu
Journal:  Theranostics       Date:  2021-06-22       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.